General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Dow Jones Futures: Tesla Robotaxi, Nvidia Chipmaker Due; Stocks Strong But These Are Scarce | news.google.com • |
B.C. man sues RBC after earning then losing $415M on Tesla stocks | news.google.com • |
B.C. man sues RBC after earning then losing $415M on Tesla stocks | news.google.com • |
Day Trader Says He Made $306 Million on Tesla, Then Lost It All | news.google.com • |
The Oncoming Market: Tesla's Robotaxi Day, JPMorgan's Q3 Kick Off | news.google.com • |
B.C. man sues RBC after earning then losing $415M on Tesla stocks | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-10-16 | 2024-09 | 0.57 | N/A | N/A | N/A |
2024-07-23 | 2024-06 | 0.62 | 0.52 | -0.1 | -16.13% |
2024-04-23 | 2024-03 | 0.46 | 0.45 | -0.01 | -2.17% |
2024-01-24 | 2023-12 | 0.75 | 0.71 | -0.04 | -5.33% |
2023-10-18 | 2023-09 | 0.72 | 0.66 | -0.06 | -8.33% |
2023-07-19 | 2023-06 | 0.83 | 0.91 | 0.08 | 9.64% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-18 | Wells Fargo | Upgrade | Equal-Weight | Equal-Weight |
2023-10-18 | Morgan Stanley | Upgrade | Overweight | Overweight |
2023-10-18 | Wedbush | Upgrade | Outperform | Outperform |
2023-10-18 | Citigroup | Upgrade | Neutral | Neutral |
2023-10-18 | Roth MKM | Upgrade | Neutral | Neutral |
2023-10-18 | Guggenheim | Upgrade | Sell | Sell |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-31 | BAGLINO ANDREW D | Officer | 31.23K | Sale |
2024-05-05 | DENHOLM ROBYN M | Director | 15.00K | Sale |
2021-10-26 | EHRENPREIS IRA MATTHEW | Director | 205.73K | Sale |
2023-08-03 | KIRKHORN ZACHARY | Chief Financial Officer | 193.79K | Sale |
2024-06-02 | MURDOCH JAMES RUPERT | Director | 407.30K | Conversion of Exercise of derivative security |
2023-03-07 | MUSK ELON REEVE | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 222.49M | 58.24B | 7.01% |
2023-06-29 | Blackrock Inc. | 185.89M | 48.66B | 5.86% |
2023-06-29 | State Street Corporation | 104.12M | 27.25B | 3.28% |
2023-06-29 | Geode Capital Management, LLC | 51.66M | 13.52B | 1.63% |
2023-06-29 | Capital World Investors | 42.27M | 11.07B | 1.33% |
2023-06-29 | FMR, LLC | 28.77M | 7.53B | 0.91% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 84.02M | 21.99B | 2.65% |
2023-06-29 | Vanguard 500 Index Fund | 64.14M | 16.79B | 2.02% |
2023-05-30 | Fidelity 500 Index Fund | 30.10M | 6.14B | 0.95% |
2023-08-30 | SPDR S&P 500 ETF Trust | 29.68M | 7.66B | 0.94% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 25.05M | 6.46B | 0.79% |
2023-08-30 | iShares Core S&P 500 ETF | 25.20M | 6.50B | 0.79% |
Split | Date |
---|---|
3 : 1 | 2022-08-25 |
5 : 1 | 2020-08-31 |
Only twice in ten years has selling TSLA been a good idea
I fully believe a successful launch pushes this stock to $950. True, Tesla is not SpaceX, but SpaceX is not a publicly traded company. Many are going to make a correlation and cause the stock to skyrocket (for no real reason). Because of this I bought two relatively cheap $980 options expiring 6/5. I think it will get a significant early Monday bounce (pre market and early market). Take your gains when you can (and feel comfortable).
Prayers for the crew and safe launch.
$TSLA I see this going over 1K if SpaceX lands successfully. (It will)
Man it must suck being short this stock all the time I would hate losing so much
plz share Amazing Smart Stock Screener app With free news ️ : Android: https://play.google.com/store/apps/details?id=com.hithink.stockscreener
iOS: https://itunes.apple.com/cn/app/id1505985895?mt=8
iOS: https://itunes.apple.com/cn/app/id1501485233?mt=8
The Best Stock Screener App Review So Far:
https://medium.com/@sherry_1022/stock-screener-app-review-242fbfdfc62
How many knew that Ocugen had a partnership which contractually GUARANTEES them revenues from Covid19 Antibody Testing?
(re: page 22 of annual report):
https://www.sec.gov/Archives/edgar/data/1372299/000110465920053502/tm2017927-1_10ka.htm
Collaboration with Advaite, Inc.
In April 2020, the Company entered into an agreement with Advaite, Inc., (Advaite) to provide certain support services for Advaite's development of a diagnostic test kit that is designed to detect antibodies to COVID-19. ...{Ocugen}... will receive tiered royalty payments based on cumulative net sales of the test kit.
The projected market for Covid diagnostic testing is $61B AND GROWING!
MORE IMPORTANTLY Advaite is NOW MOVING on Covid Antibody Testing!
https://www.linkedin.com/mwlite/company/advaite
*
The BEAUTY here:
NOBODY KNOWS Ocugen will be collecting potentially BILLION$ in COVID DIAGNOSTICS revenue! They NEVER did a PRESS RELEASE!
How do you see profiles on this app?
Who bought puts in the 780s an fell for that bear trap hahahaha
Lol everyone freaking out like they didn’t expect car sales to go down in a recession what a stupid drop
Who wants to mine some crypto? Pi is a new digital currency developed by Stanford PhDs, with over 3.5 million members worldwide. Earn Pi for free... follow this link https://minepi.com
Invite only - use (JakeShwis) as your invite.
You can thank me later.
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!